Xenon Pharmaceuticals Inc.
Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

Abstract:

This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.